scholarly journals Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia

2019 ◽  
Vol 7 (7) ◽  
pp. 1106-1119 ◽  
Author(s):  
Yorleny Vicioso ◽  
Hermann Gram ◽  
Rose Beck ◽  
Abhishek Asthana ◽  
Keman Zhang ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia ◽  
Drug Resistant

Abstract 3186: A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia

2019 ◽  
Author(s):  
Yorleny M. Vicioso ◽  
Rose Beck ◽  
Herman Gram ◽  
Abhishek Asthana ◽  
keman Zhang ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia ◽  
Drug Resistant

Abstract 3186: A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia

2019 ◽  
Author(s):  
Yorleny M. Vicioso ◽  
Rose Beck ◽  
Herman Gram ◽  
Abhishek Asthana ◽  
keman Zhang ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia ◽  
Drug Resistant

Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia

Oncogene ◽  
2020 ◽  
Vol 39 (42) ◽  
pp. 6544-6555
Author(s):  
Deborah Bongiovanni ◽  
Valeria Tosello ◽  
Valentina Saccomani ◽  
Silvia Dalla Santa ◽  
Alberto Amadori ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Combination Therapy ◽  
Glucocorticoid Receptor ◽  
Lymphoblastic Leukemia ◽  
Hedgehog Pathway ◽  
Cell Acute Lymphoblastic Leukemia

Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia

2010 ◽  
Vol 52 (1) ◽  
pp. 137-141 ◽  
Author(s):  
Takaaki Okamoto ◽  
Katsuyoshi Koh ◽  
Junko Takita ◽  
Ayaka Furuya ◽  
Motohiro Kato ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia

scholarly journals Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Blood ◽  
2017 ◽  
Vol 129 (11) ◽  
pp. e26-e37 ◽  
Author(s):  
Viktoras Frismantas ◽  
Maria Pamela Dobay ◽  
Anna Rinaldi ◽  
Joelle Tchinda ◽  
Samuel H. Dunn ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Drug Response ◽  
Ex Vivo ◽  
Lymphoblastic Leukemia ◽  
Drug Repurposing ◽  
Therapeutic Agents ◽  
Drug Resistant ◽  
Key Points

Key Points Ex vivo drug profiling captures disease-relevant features and relevant sensitivity to therapeutic agents in ALL. A subset of drug-resistant T-ALL without mutations in ABL1 is highly responsive to dasatinib, which provides a rationale for drug repurposing.

scholarly journals Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

2017 ◽  
Vol 10 (3) ◽  
pp. 381-389
Author(s):  
NA Batmanova ◽  
◽  
MA Shervashidze ◽  
AV Popa ◽  
LYu Grivtsova ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia ◽  
Leukemia In Children
Sign in / Sign up

Export Citation Format

Share Document